Pharmaceuticals

Global Remicade Biosimilar Market Expected To Reach $55.21 Billion By 2030 With 5.4% CAGR

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Remicade Biosimilar Market Expected To Scale Between 2026 And 2030?

The remicade biosimilar market size has experienced significant expansion over recent years. It is anticipated to expand from $4.89 billion in 2025 to $5.97 billion in 2026, growing at a compound annual growth rate (CAGR) of 22.2%. The historical increase can be ascribed to several factors, including the substantial cost burden associated with branded biologics, the expiration of remicade’s patent, a rising incidence of autoimmune diseases, governmental encouragement for biosimilar approvals, and procurement models driven by hospitals for bulk purchases.

The remicade biosimilar market size is projected to experience substantial growth over the coming years. This market is anticipated to reach $13.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. This anticipated growth is driven by several factors, including an increasing need for economical biologic treatments, the expansion of biosimilar development pipelines, higher healthcare spending in developing nations, greater acceptance among medical professionals and individuals, and supportive reimbursement structures. Key trends foreseen for this period encompass a greater embrace of affordable biosimilars, growing confidence among prescribers regarding infliximab biosimilars, broader application for various autoimmune conditions, competitive pricing strategies combined with tender-based purchasing, and deeper market penetration in nascent healthcare sectors.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Key Factors Are Shaping The Remicade Biosimilar Market Landscape?

The rising prevalence of autoimmune diseases is projected to boost the expansion of the remicade biosimilar market in the future. Autoimmune diseases are conditions where the immune system mistakenly targets and damages the body’s own tissues and organs. Remicade biosimilars are utilized in treating these illnesses, providing a valuable therapeutic option to manage symptoms and reduce inflammation. For example, in February 2024, Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, approximately 562,378 Australians are anticipated to be living with rheumatoid arthritis (RA), comprising 14% of the total arthritis population. The number of individuals with RA is forecast to climb by 33%, reaching around 748,721 by 2040. Hence, the increasing incidence of autoimmune diseases is a significant factor propelling the growth of the remicade biosimilar market.

How Is The Remicade Biosimilar Market Categorized Across Its Segment Groups?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

What Trends Are Shaping The Future Of The Remicade Biosimilar Market?

Leading companies in the Remicade biosimilar market are concentrating on developing innovative solutions, such as subcutaneous formulations, to achieve a competitive advantage. Subcutaneous Remicade formulations present an alternative method of administration for treating autoimmune diseases, facilitating self-administration and potentially enhancing patient adherence to their therapy. For instance, Celltrion, a biopharmaceutical company based in South Korea, launched Zymfentra in March 2024. This biosimilar to Remicade (infliximab) is priced at $6,181.08 for two doses over four weeks and received FDA approval as the first subcutaneous infliximab formulation for maintenance therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Eligible commercially insured patients can access copay assistance of $5 per month, while Zymfentra may be provided at no cost for uninsured or underinsured patients.

Which Firms Are Influencing Competition In The Remicade Biosimilar Market?

Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A

Get The Full Remicade Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Where Is The Remicade Biosimilar Market Most Concentrated Geographically?

Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Remicade Biosimilar Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2026, By The Business Research Company

Remicade Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Biotechnology Reagents Market Report 2026

https://www.thebusinessresearchcompany.com/report/biotechnology-reagents-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795